The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to ElevateBio. (``Elevate''), located in Cambridge, MA.
Document
Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like Tyrosine Kinase 3 (FLT3) Expressing Cancers
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent Lice...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 58262
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like Tyrosine Kinase 3 (FLT3) Expressing Cancers,” thefederalregister.org (November 19, 2018), https://thefederalregister.org/documents/2018-25197/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-chimeric-antigen-receptor-car-ther.